Project Grant R43HL177857
Award Date
4/20/25
Completion Date
3/31/26
Dollars Obligated
$306K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Florida, USA
Similar Awards
This $590,390 Project Grant from the National Heart, Lung and Blood Institute of the Department of Health and Human Services will support the development of a clinically applicable blood test to enhance personalized assessment of coronary risk. Awardee Proteas Bioanalytics Inc. will partner with Johns Hopkins researchers to discover plasma and cell proteomic signatures closely correlated with coronary vascular function as measured by cardiac MRI. Johns Hopkins will perform MRI studies on...
The $265,347 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports Functional Fluidics Inc.'s development of a rapid, integrated test for assessing red blood cell sickling in sickle cell disease. The key product is a stand-alone, potentially CLIA-waived point-of-care device with disposable cartridges to monitor patient condition and treatment efficacy, especially for drugs affecting...
The National Heart, Lung, and Blood Institute (NHLBI) awarded Kilele Health Inc. a $539,041 Project Grant under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) to develop a factory-calibrated continuous multi-modal molecular monitor for heart failure patients. The proposed device would enable remote monitoring of critical biomarkers such as NT-proBNP and potassium levels, with the goal of improving treatment management, reducing hospital readmissions, and optimizing care...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $295,892 to Asclepia Technology LLC to conduct a proof-of-concept study on a targeted cellular therapy for treating atherosclerotic vascular disease in minority patients. The funding will support the development and evaluation of dual-functional, echogenic immunoliposomes (DF-ELIP) that can deliver vascular stem cells (VSC) to...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), aims to develop a rapid, low-cost, point-of-care (POC) diagnostic platform for quantitatively measuring placental growth factor (PLGF) to predict and detect pre-eclampsia. The $295,895 award to Ricovr Healthcare Inc., a minority-owned small business, supports the feasibility demonstration of using Ricovr's plasmonic fiber-optic absorbance biosensor (P-FAB)...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), awarded a $299,604 Project Grant to Case Western Reserve University (CWRU) to develop and validate a novel "transfer volume regression" machine learning model for predicting major cardiovascular events, including stroke, heart attack, heart failure, and death. The 4-year project, starting September 1, 2024, aims to create a standardized, fairness-aware,...
This Project Grant award for $827,665 was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837). The award aims to develop scalable methods to address key challenges in cardiovascular disease (CVD) genome-wide association studies. Specifically, the grant will fund research to: 1) identify causal genetic variants associated with CVD, 2) determine the most relevant cell types for these variants, and 3)...
This Project Grant award from the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $343,203 to Cyion Technologies LLC to develop a novel in vitro electrophysiology system for high-throughput measurement of intracellular action potential (IAP) in human-derived cardiomyocytes. The system leverages a 3D nanoelectrode array (NEA) technology to enable scalable recordings of IAP signals from many individual cardiomyocytes. This...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of novel P7C3-based small molecules for the treatment of heart failure. The University of South Florida, a major public research university, will utilize $517,475 over the award period from September 2024 to July 2026 to conduct medicinal chemistry, in vitro assays, ex vivo studies, and in vivo preclinical evaluation of...
This federal Project Grant award of $321,363 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is for the development and testing of Nucleusrx, Inc.'s virtual care platform and remote intervention tool. The platform aims to reduce emergency re-hospitalizations in heart failure patients transitioning from the hospital to home. The key products and services to be delivered over the 1-year project period include: 1)...